Background Tumor necrosis factor inhibitory agents are currently considered to be
contraindicated in psoriatic patients with hepatitis B. Objective We aim to provide guidance …

Background Issues concerning the potential risks of reactivating chronic hepatitis B virus
arise when the use of anti‐Tumour Necrosis Factor‐α (TNFα) agents is imperative in patients …

Background No consensus exists regarding the optimal laboratory screening for hepatitis B
infection that should be performed before initiating therapy with tumor necrosis factor-alfa …

The use of anti‐tumor necrosis factor (TNF)‐α therapy in patients with psoriasis who are
hepatitis B virus (HBV) carriers is usually not recommended, and routine antiviral …

Introduction Tumour necrosis factor (TNF)‐α antagonists are effective for the treatment of
plaque‐type psoriasis and psoriatic arthritis, but concerns remain about the safety of these …

Considered more efficacious and safer than traditional systemic drugs, biologic therapies
have dramatically improved the quality of life of patients with psoriasis. Recently, there has …

Background Recently, the reactivation during treatment with tumor necrosis factor (TNF)
blockers has exceptionally been described in patients with hepatitis B virus (HBV) antigen …

Background The increasing use of biologics is accompanied by a risk of hepatitis B (HBV)
and C virus (HCV) reactivation. Objective To determine the predictors of HBV and HCV …

Objective The aim of the study was to assess dermatologists' awareness of available
guidelines and drug package insert information on the screening for and management of …

Background Little data are available about the safety of TNF‐α inhibitors in patients with
HCV and HBV infection. In particular, data concerning the use of adalimumab in patients …